Unlocking the mysteries of nutrition, treatment and clinical trials: 

Spotlight on Pancreatic and Stomach Cancer, the silent killers

Friday 27 November 2020

11:30am – 12:15pm (AEDT)


Register now

Pancreatic cancer and Stomach cancer are often called the silent killers. They are difficult to detect and survival rates are tragically low. But more than 6,000 Australians will be diagnosed with one of these diseases this year.

In recognition of pancreatic and stomach cancer awareness month in November, our guest speakers Medical Oncologist Associate Professor Nick Pavlakis and Clinical Dietitian Belinda Steer, will discuss all facets of managing these cancers from study design challenges through to the importance of nutrition during and after treatment.

Our guest speakers will discuss:

  • Challenges in designing studies and recruiting patients for trials in pancreatic and stomach cancers
  • Clinical issues in stomach and pancreatic cancer
  • Importance of nutrition in pancreatic and stomach cancers
  • A case study for each cancer showing what is currently being done to improve treatments

It’s free to register and you will have the opportunity to ask questions live to our guest speakers.

Don’t miss your chance to attend.


Register now



Associate Professor Nick Pavlakis, Senior Staff Specialist, Medical Oncology, Royal North Shore Hospital, Sydney 

Associate Professor Nick Pavlakis is a Medical Oncologist with 20 years of experience in the field of oncology, clinical and translational research, with a special interest in the development of new cancer drugs. Dr Nick Pavlakis is Senior Staff Specialist in the Department of Medical Oncology at Royal North Shore Hospital and conjoint Associate Professor in the Faculty of Medicine University of Sydney. He is current Board Chair of the new Thoracic Oncology Group of Australasia (TOGA) and President of the Clinical Oncologic Society of Australia (COSA).

His background includes a PhD in anti-angiogenic cancer drug development and a Masters of Clinical Epidemiology (University of Sydney). He has extensive experience in clinical research leadership in national and international clinical trials in lung cancer, mesothelioma and GI cancers with several current and ongoing collaborative group trials in lung cancer, gastric cancer and NETs – he is the co-chair of the AGITG CONTROL NET studies and INTEGRATE studies and member of the Upper GI Working Group of AGITG.

As co-chair of the Bill Walsh Translational Research Laboratories he is involved in translational research evaluating TKI resistance in NSCLC and biomarkers in lung cancer, pancreas and gastric cancers.  He is the Chair of the ENETS Centre of Excellence in Neuroendocrine tumours based at Royal North Shore Hospital – Sydney Theranostics North. Putting evidence into practice he has contributed to systematic reviews and clinical practice guideline development.

Belinda Steer, Joint Head of the Nutrition and Speech Pathology Department, Peter MacCallum Cancer Centre, Melbourne

Belinda Steer is an accredited practicing Dietitian with over 10 years experience in clinical nutrition. Her passion for oncology nutrition stems from her desire to improve the patients’ experience during their cancer journey.

Belinda specialises in upper gastrointestinal cancers and is a strong advocate for patient-centred care, working very closely with her multidisciplinary team to ensure her patients nutritional status is optimised at all times.

Belinda has worked on a number of projects that have focused on implementing the evidence with regards to identifying and managing malnutrition in the oncology setting, with the overall goal to improve patient outcomes; and she has presented many pieces of this work at national conferences.


About the GI Cancer Institute

The GI Cancer Institute is a not-for-profit charity dedicated to improving the health and quality of life of patients with Gastro-Intestinal (GI) cancer by developing and conducting impartial and collaborative multi-disciplinary clinical trials which include health professionals, patients and consumers.

GI cancer includes the digestive organs: oesophagusstomachlivergallbladder and biliary tractpancreaslarge and small bowelrectum and anus. Together these cancers are the most common forms of cancer, with 28,600 Australians diagnosed every year and claiming a devastating 39 lives a day.

The GI Cancer Institute works to raise funds and awareness of GI cancer and clinical trials, and through its AGITG members it develops and delivers rigorous best practice clinical trials for Gastro-Intestinal cancer patients. The AGITG membership encompasses a wide range of medical specialists, scientists, nurses, allied health professionals and consumers involved in all aspects of Gastro-Intestinal cancer research.